Highlights
In this retrospective analysis, patients with myelodysplastic neoplasms (MDS) with isolated del(5q) and TP53 multihit alterations had markedly better overall survival and slower acute myeloid leukemia (AML) progression than patients with other low-blast TP53-multihit MDS.
The reported median overall survival was 70.2 months for MDS-del(5q) TP53 multihit versus 13.9 months for low-blast MDS TP53 multihit without isolated del(5q), with corresponding times to AML progression of 31.9 versus 7.2 months.
